Clinical trials: Acute Granulocytic Leukemia
CD123+ Acute Myeloid Leukemia
Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression
The goal of this Phase 1 clinical trial is to understand whether a new experimental treatment, called ORM-1153, will be a safe and possibly effective treatment option for participants with blood cancers such as Acute Myeloid…
- Trial name
- NCT07809906
- Testing
- ORM-1153
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Orum Therapeutics USA, Inc.
Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia (CML), Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia (ALL)
Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)
This study will evaluate a gene expression signature (Growth Factor Signature [GFS]) as a biomarker for response/resistance to BRC-ABL oncogene inhibitors.
- Trial name
- NCT00860535
- Testing
- Comparator: Biomarker evaluation
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
AML, Adult
A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML
An open label multi centre study to assess the safety and efficacy of BST-236 in combination with venetoclax in adult patients unfit for standard therapy with newly diagnosed Acute Myeloid Leukemia (AML) Part 1 of the study will…
- Trial name
- NCT05503355
- Testing
- BST-236, venetoclax
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- BioSight Ltd.
Acute Myeloid Leukemia
Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia
To evaluate the tolerability and pharmacokinetics of SGI-110 when administered subcutaneously to Japanese patients with acute myeloid leukemia (AML).
- Trial name
- NCT02293993
- Testing
- SGI-110
- Where
- 3 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL)
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
This study is an open-label, controlled, multicenter, international, Phase III, randomized study of transplantation of NiCord® versus transplantation of one or two unmanipulated, unrelated cord blood units in patients with acute…
- Conditions
- Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT02730299
- Testing
- NiCord® (omidubicel), Cord Blood Unit
- Where
- 52 sites in United States, Brazil and 8 more
- Volunteers
- 125 people
- Sponsor
- Gamida Cell ltd
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
This study, is a Phase I/II clinical trial in three parts: Phase I Dose Escalation, Phase II, Part 1 RPTD Cohort, and Phase II, Part 2 Expansion. The first two parts have been completed.
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT01926587
- Testing
- oral rigosertib, Azacitidine
- Where
- 13 sites in United States, France
- Volunteers
- 45 people
- Sponsor
- Traws Pharma, Inc.
Acute Myeloid Leukemia
Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML
Assessment of safety and tolerability of drug combination and determine time on treatment, Overall survival (OS) and response rate with patient disease burden, and type of disease
- Trial name
- NCT02875093
- Testing
- ADI-PEG 20, Cytarabine
- Where
- 3 sites in Taiwan
- Volunteers
- 23 people
- Sponsor
- Polaris Group
Acute Lymphoblastic Leukemia, With KMT2A Rearrangements, Acute Myeloid Leukemia, With NPM1 Mutations
Expanded Access to Ziftomenib
Requests for single patient expanded access to ziftomenib monotherapy may be considered for eligible adult patients with Acute Lymphoblastic Leukemia (ALL) with KMT2A rearrangements, or Acute Myeloid Leukemia (AML), with KMT2A…
- Conditions
- Acute Lymphoblastic Leukemia, With KMT2A Rearrangements, Acute Myeloid Leukemia, With NPM1 Mutations, Acute Myeloid Leukemia, With KMT2A Rearrangements
- Trial name
- NCT05738538
- Testing
- ziftomenib
- Sponsor
- Kura Oncology, Inc.
Neoplasms, Myelogenous Leukemia, Acute
A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.
This open label, Phase I study of RO6839921 is a dose-escalation study with two arms. Prior to investigations in either arm, patients in a single cohort, Cohort 0, will receive non-escalating, intravenous (IV) doses of RO6839921…
- Trial name
- NCT02098967
- Testing
- RO6839921
- Where
- 5 sites in United States, Canada
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
The purpose of this study is to determine whether ATIR is safe and effective in reducing transplant-related mortality and improving overall survival, when infused in patients with a hematologic malignancy following a T-cell…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01794299
- Testing
- ATIR
- Where
- 8 sites in Belgium, Canada and 2 more
- Volunteers
- 31 people
- Sponsor
- Kiadis Pharma
Acute Myeloid Leukemia
A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
This open-label, entry-into-human (EIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of RO7283420.
- Trial name
- NCT04580121
- Testing
- RO7283420, Tocilizumab, Dasatinib
- Where
- 23 sites in United States, Australia and 8 more
- Volunteers
- 59 people
- Sponsor
- Hoffmann-La Roche
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
The purpose of the study is to determine how effective azacitidine, MGCD0103, and the combination of azacitidine and MGCD0103 are in treating AML or MDS in people over 60 years of age.
- Trial name
- NCT00666497
- Testing
- Azacitidine, MGCD0103
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 6 people
- Sponsor
- Mirati Therapeutics Inc.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
Acute myeloid leukemia is a malignant disorder characterized by the rapid, uncontrolled proliferation of malignant clonal hematopoietic stem cells that accumulate as immature, undifferentiated cells (blasts) in the bone marrow…
- Trial name
- NCT04275518
- Testing
- APG-115, Azacitidine, Cytarabine
- Where
- 14 sites in China
- Volunteers
- 102 people
- Sponsor
- Ascentage Pharma Group Inc.
Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia (APL)
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
This clinical study will demonstrate the accuracy of the chromosomal aberration and gene mutation markers of the AMLProfiler molecular diagnostic assay and generate clinical performance data to support a Pre-Market Approval (PMA)…
- Conditions
- Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia (APL), Refractory Anemia With Excess of Blasts (RAEB)
- Trial name
- NCT01463410
- Where
- 5 sites in United States, Germany and 2 more
- Volunteers
- 264 people
- Sponsor
- Skyline Diagnostics BV
Hematological Malignancies
Study of IV CBL0137 in Previously Treated Hematological Subjects
This clinical trial is a Phase 1, open-label, sequential-group, dose-escalation (Part 1) and cohort-expansion study (Part 2) evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of intravenously (IV)…
- Trial name
- NCT02931110
- Testing
- CBL0137
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incuron
Acute Myelogenous Leukemia
Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant
The primary objective of this study is to evaluate the safety of gemtuzumab ozogamicin in relapsed CD33-positive AML patients who received HSCT. If the MTD dose is not reached, 9 mg/m2 will be the maximum tested dose.
- Trial name
- NCT00044733
- Testing
- Mylotarg (gemtuzumab ozogamicin) Injection
- Where
- 13 sites in United States
- Volunteers
- 38 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Acute Myeloid Leukemia
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse after treatment or who don't respond to treatment.
- Trial name
- NCT07306832
- Testing
- Pivekimab Sunirine
- Where
- 14 sites in United States, Australia and 5 more
- Volunteers
- 18 people
- Sponsor
- AbbVie
Leukemia, Myeloid, Acute
Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission
This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) or AML secondary to prior myelodysplastic disease or chronic myelomonocytic leukemia (CMML), and who have achieved…
- Trial name
- QUAZAR AML-001 (NCT01757535)
- Testing
- Oral Azacitidine
- Where
- 223 sites in United States, Australia and 21 more
- Volunteers
- 472 people
- Sponsor
- Celgene
Hematological Malignancies
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogneic signal is present.
- Trial name
- NCT00438178
- Testing
- Obatoclax mesylate (GX15-070MS)
- Where
- 3 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- Gemin X
Relapsed AML, Refractory AML
Phase 1 Study of Quizartinib
This is a dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of quizartinib for Japanese acute myeloid leukemia (AML) subjects.
- Trial name
- NCT02675478
- Testing
- AC220
- Where
- Japan
- Volunteers
- 17 people
- Sponsor
- Daiichi Sankyo Co., Ltd.